Boston, July 10, 2025 (GLOBE NEWSWIRE) — According to the latest study from BCC Research, the “Current R&D Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy Market” is expected to grow from $4.6 billion in 2024 to $25.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 40.2% from 2024 to 2029.
This report offers a comprehensive analysis of the CAR T-cell therapy market, focusing on current R&D status and market trends. It includes profiles of leading market players, their products, financial data, and recent activity.
The report also examines business strategies in the competitive landscape, historical development, ongoing advances, and CAR T-cell therapy regulatory requirements. Additionally, it provides a regional analysis covering the U.S. and international markets.
The factors driving the market’s growth include:
Increasing Incidence of Cancer: The rising number of cancer cases globally is a significant driver for CAR T-cell therapy. CAR T-cell therapy, which involves modifying a patient’s T-cells to target and destroy cancer cells, offers a promising treatment for cancer.
Growing Investments and Funding in CAR T-cell Therapy Research: There has been a substantial increase in investments and funding from the public and private sectors. This financial support accelerates R&D, advancing CAR T-cell therapy and bringing new treatments to market more quickly.
Strong Research and Development Pipeline: The R&D pipeline for CAR T-cell therapy is robust, with numerous clinical trials and studies underway. This strong pipeline indicates a continuous flow of new and improved therapies, enhancing the potential for successful treatments and expanding the market.
Advances in Genetic Engineering: Technological advances in genetic engineering have significantly improved the efficacy and safety of CAR T-cell therapies. Innovations such as CRISPR and other gene-editing tools allow for more precise modifications of T-cells, leading to better-targeted therapies with fewer side effects.
Growing Significance of Precision Medicine: Precision medicine, which tailors treatments to individual patients based on their genetic makeup is becoming increasingly important in healthcare. CAR T-cell therapy aligns well with this approach, as it involves customizing T-cells to target specific cancer cells in each patient, leading to more effective and personalized treatments.
Expanding Applications of CAR T-cell Therapy: Initially, CAR T-cell therapy was primarily used for certain types of blood cancers. However, ongoing research is expanding its applications to other cancer types, including solid tumors. This broadening scope increases the potential market for CAR T-cell therapies and drives further R&D.
Request a sample copy of the global market for CAR T-cell therapy report.
Report Synopsis
| Report Metric | Details |
| Base year considered | 2023 |
| Forecast period considered | 2024-2029 |
| Base year market size | $4.6 billion |
| Market size forecast | $25.1 billion |
| Growth rate | CAGR of 40.2% from 2024 to 2029 |
| Segments covered | Product, Indication, and Region |
| Regions covered | U.S. and International markets |
| Market drivers |
|
Interesting facts:
- Over 210 CAR T cell therapy businesses are working on creating potential treatments for oncological, non-oncological, and other diseases.
- As of January 2023, approximately 1,087 clinical trials involving CAR T-cells were registered on ClinicalTrials.gov (Research registry ID: reviewregistry1542).
Emerging startups:
- Capstan Therapeutics: Founded in 2021 and based in U.S., Capstan Therapeutics uses an innovative approach of programming T-cells in the body, as compared to other companies that engineer T-cells in the lab. This is done by using mRNA vectors in which CARs are encoded and delivered via lipid nanoparticles.
- Verismo Therapeutics: The company was founded in 2021 and is based in the U.S. The company’s CAR T-cell therapies platform, the KIR-CAR platform, is based on engineering T cells that make tumor-busting natural killer cells to express proteins.
The report addresses the following questions:
- What is the projected market size and growth rate?
- The global CAR T-cell therapy market was valued at $4.6 billion in 2024. It is projected to reach $25.1 billion by the end of 2029, at an estimated CAGR of 40.2% from 2024 to 2029.
- What are the factors driving the growth of the market?
- Key market drivers include:
- Increasing incidence of cancer.
- Growing investments and funding in CAR T-cell therapy research.
- Strong R&D pipeline.
- Advances in genetic engineering.
- Which market segments are covered in the report?
- The report analyzes the CAR T-cell therapy market and its growth projections in the forecast period. The market segments covered in the report include product type, indication type, and regional data for the U.S. and international markets. The report also provides information about clinical trials, the patent landscape, regulatory requirements, and the competitive landscape.
- Which product type segment will be dominant through 2029?
- The Yescarta product segment dominates the CAR T-cell therapy market and will continue to do so through 2029.
- Which region has the largest market share?
- The U.S. holds the largest share of the market.
Market leaders include:
- ABBVIE INC.
- ALLOGENE THERAPEUTICS
- AMGEN INC.
- ASTRAZENECA
- BLUEBIRD BIO INC.
- BRISTOL-MYERS SQUIBB CO.
- CELLECTIS S.A.
- EUREKA THERAPEUTICS INC.
- GILEAD SCIENCES INC.
- ICELL GENE THERAPEUTICS INC.
- JOHNSON & JOHNSON SERVICES INC.
- LES LABORATOIRES SERVIER
- NOVARTIS AG
- PFIZER INC.
- PROTHERAGEN INC.
Related reports:
Global Oncology Pharmaceuticals Market: This report provides a comprehensive analysis of the global oncology pharmaceuticals market, covering drug types like targeted therapy, immunotherapy, chemotherapy, and hormone therapy. It examines market revenues and categorizes the market by cancer indications, including lung cancer, multiple myeloma, breast cancer, non-Hodgkin’s lymphoma, prostate cancer, and colorectal cancer. The report also covers market revenues by region—North America, Europe, Asia-Pacific, and Rest of the World—and includes profiles of leading companies, competitive landscape, market share rankings, pipeline and patent analyses, and discussions of key marketed products.
Antibody Drugs: Technologies and Global Markets: This report provides a global overview of antibody drugs, focusing on therapeutic applications of monoclonal antibodies (mAbs) and antibody drug conjugates (ADCs). It analyzes the market, regulatory environment, and technological advances, and includes profiles of leading companies like AbbVie, Amgen, Johnson & Johnson, Roche, and Merck. The report covers applications in autoimmune diseases, solid tumors, lymphoma, leukemia, and other chronic diseases. The market is segmented by region into North America, Europe, Asia-Pacific, and the Rest of the World.
Purchase a copy of the report direct from BCC Research.
For further information on any of these reports or to make a purchase, contact info@bccresearch.com.
About BCC Research
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts’ goal is to help you make informed business decisions free of noise and hype.
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow